Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/7626
Title: Trypanosoma cruzi adjuvants potentiate T Cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine
Authors: Giusta, Caroline Junqueira
Guerrero, Ana Tereza
Galvão Filho, Bruno
Andrade, Warrison Athanásio Coelho de
Salgado, Ana Paula Carneiro
Cunha, Thiago Mattar
Ropert, Catherine
Campos, Marco Antônio da Silva
Penido, Marcus Luiz de Oliveira
Previato, Lúcia Mendonça
Previato, Jose Oswaldo
Ritter, Gerd
Cunha, Fernando Queiroz
Gazzinelli, Ricardo Tostes
Affilliation: Fundaçao Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratorio de Imunopatologia. Belo Horizonte,MG, Brazil/Universidade Federal de Minas Gerais. Departamento de Bioquımica e Imunologia. Belo Horizonte, MG, Brazil
Fundaçao Oswaldo Cruz. Instituto Cerrado Pantanal. Campo Grande, MT, Brazil
Fundaçao Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratorio de Imunopatologia. Belo Horizonte,MG, Brazil/Universidade Federal de Minas Gerais. Departamento de Bioquımica e Imunologia. Belo Horizonte, MG, Brazil,
Fundaçao Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratorio de Imunopatologia. Belo Horizonte,MG, Brazil/Universidade Federal de Minas Gerais. Departamento de Bioquımica e Imunologia. Belo Horizonte, MG, Brazil/University of Massachusetts. Medical School. Division of Infectious Diseases and Immunology. Worcester, MA, United States of America
Fundaçao Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratorio de Imunopatologia. Belo Horizonte,MG, Brazil
Universidade de Sao Paulo. Faculdade de Medicina de Ribeirao Preto. Departamento de Farmacologia. Ribeirao Preto, SP, Brazil
Fundaçao Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratorio de Imunopatologia. Belo Horizonte,MG, Brazil
Fundaçao Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratorio de Imunopatologia. Belo Horizonte,MG, Brazil
Universidade Federal de Minas Gerais. Departamento de Bioquımica e Imunologia. Belo Horizonte, MG, Brazil
Instituto de Biofısica Carlos Chagas Filho. Centro de Ciencias da Saude. Universidade Federal do Rio de Janeiro. Rio de Janeiro, Brazil
Instituto de Biofısica Carlos Chagas Filho. Centro de Ciencias da Saude. Universidade Federal do Rio de Janeiro. Rio de Janeiro, Brazil
New York Branch at Memorial Sloan–Kettering Cancer Center.Ludwig Institute for Cancer Research. New York, New York, United States of America
Universidade de Sao Paulo. Faculdade de Medicina de Ribeirao Preto. Departamento de Farmacologia. Ribeirao Preto, SP, Brazil
Fundaçao Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratorio de Imunopatologia. Belo Horizonte,MG, Brazil/Universidade Federal de Minas Gerais. Departamento de Bioquımica e Imunologia. Belo Horizonte, MG, Brazil/University of Massachusetts. Medical School. Division of Infectious Diseases and Immunology. Worcester, MA, United States of America
Abstract: Immunological adjuvants that induce T cell-mediate immunity (TCMI) with the least side effects are needed for the development of human vaccines. Glycoinositolphospholipids (GIPL) and CpGs oligodeoxynucleotides (CpG ODNs) derived from the protozoa parasite Trypanosoma cruzi induce potent pro-inflammatory reaction through activation of Toll-Like Receptor (TLR) 4 and TLR9, respectively. Here, using mouse models, we tested the T. cruzi derived TLR agonists as immunological adjuvants in an antitumor vaccine. For comparison, we used well-established TLR agonists, such as the bacterial derived monophosphoryl lipid A (MPL), lipopeptide (Pam3Cys), and CpG ODN. All tested TLR agonists were comparable to induce antibody responses, whereas significant differences were noticed in their ability to elicit CD4(+) T and CD8(+) T cell responses. In particular, both GIPLs (GTH, and GY) and CpG ODNs (B344, B297 and B128) derived from T. cruzi elicited interferon-gamma (IFN-gamma) production by CD4(+) T cells. On the other hand, the parasite derived CpG ODNs, but not GIPLs, elicited a potent IFN-gamma response by CD8(+) T lymphocytes. The side effects were also evaluated by local pain (hypernociception). The intensity of hypernociception induced by vaccination was alleviated by administration of an analgesic drug without affecting protective immunity. Finally, the level of protective immunity against the NY-ESO-1 expressing melanoma was associated with the magnitude of both CD4+ T and CD8+ T cell responses elicited by a specific immunological adjuvant.
Keywords: Trypanosoma cruzi
immunology
Issue Date: 2012
Publisher: Public Library of Science
Citation: JUNQUEIRA, Caroline et al. Trypanosoma cruzi adjuvants potentiate T Cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine. Plos One. 2012, vol.7, pp. e36245
DOI: 10.1371/journal.pone.0036245
ISSN: 1932-6203
Copyright: open access
Appears in Collections:MG - IRR - Artigos de Periódicos



FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.